Together the findings in vitro indicated that tumour rejection using Her2MPyVLPs and Her2MPtVLPs was primarily mediated by CD8+ cytotoxic T cells, but whether other immune cells were also involved was never pursued. The gene discussed is CD8A; the disease is neoplasm.